Blood Disorders Therapeutics
1. Empaveli patent expiration
Treatment: Treatment of adult and pediatric patients aged 12 years and older weighing 50 kg or higher with c3g or primary ic-mpgn by twice weekly subcutaneous administration of a unit dose of 1080 mg ofpegcetaco...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(7 years from now) | |
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(7 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(7 years from now) | |
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(1 year, 10 months from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(7 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(1 year, 10 months from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(7 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12290566 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Dec, 2038
(12 years from now) | |
| US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(12 years from now) | |
| US11844841 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Dec, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-288) | Feb 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
| New Indication(I-972) | Jul 28, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Dosage: SOLUTION
More Information on Dosage
EMPAVELI family patents
2. Fabhalta patent expiration
Treatment: Treatment of complement 3 glomerulopathy (c3g) by administration of 200 mg of iptacopan twice daily; Treatment of paroxysmal noctural hemoglobinuria (pnh) by administration of 200 mg of iptacopan twic...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9682968 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(8 years from now) | |
| US11603363 | NOVARTIS | Crystalline form of LNP023 |
May, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12285422 | NOVARTIS | Uses of piperidinyl-indole derivatives |
Aug, 2038
(12 years from now) | |
| US12453726 | NOVARTIS | NA |
Jul, 2041
(15 years from now) | |
| US10093663 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(8 years from now) | |
| US12384758 | NOVARTIS | NA |
May, 2041
(15 years from now) | |
| US11951101 | NOVARTIS | Methods of using factor B inhibitors |
Jul, 2041
(15 years from now) | |
| US11723901 | NOVARTIS | Uses of piperidinyl-indole derivatives |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-949) | Aug 07, 2027 |
| New Indication(I-963) | Mar 20, 2028 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Dosage: CAPSULE
More Information on Dosage
FABHALTA family patents
3. Tavalisse patent
expiration
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
TAVALISSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7538108 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(2 months from now) | |
| US7989448 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8163902 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8211889 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US7449458 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737554 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8951504 | RIGEL PHARMS | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(6 years from now) | |
| US8912170 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US9283238 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US9266912 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8445485 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(5 months from now) | |
| US8652492 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2028
(2 years from now) | |
| US8263122 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2030
(4 years from now) | |
| USRE48898 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(10 days from now) | |
| US8771648 | RIGEL PHARMS | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents
4. Voydeya patent expiration
Treatment: Treatment of extravascular hemolysis (evh) in adults with paroxysmal nocturnal hemoglobinuria (pnh) as add-on therapy to ravulizumab or eculizumab
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796741 | ALEXION PHARMS INC | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076319 | ALEXION PHARMS INC | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
| Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
Drugs and Companies using DANICOPAN ingredient
NCE-1 date: 29 March, 2028
Market Authorisation Date: 29 March, 2024
Dosage: TABLET
More Information on Dosage
VOYDEYA family patents